Develops and distributes nutraceuticals, bioceuticals, and dietary supplements. Now — the numbers.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
This is an established company with proven profits.
Average growth of 609% a year over the last 4 years. Red columns mark years that ended in a loss.
If every debt were paid off today, $2.1M would still be left in the vault — a solid cushion for hard times.
The market pays 7.1× for every dollar of annual profit — cheap, which is either an opportunity or a warning.
No analyst target is on record for this company.
Executives buying with their own money is usually read as confidence in the company’s future.
An investor who bought at the very peak is down 72% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 4 years, sales grew about 609% a year on average.
There is $2.2M in the vault; even if every debt were paid off, $2.1M would remain.
Over the last 12 months, company executives reported 64 buys and 0 sells. Management buying with its own money is usually read as a good sign.
The stock sits at $0.09. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
This stock swings about 2.5 times as much as the market average. Big rallies — and big drops — can both happen fast.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: earnings execution.